Drug Resistance in Plasma and Breast Milk after Single-Dose Nevirapine in Subtype C HIV Type 1: Population and Clonal Sequence Analysis
- 1 August 2007
- journal article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 23 (8) , 1055-1061
- https://doi.org/10.1089/aid.2007.0045
Abstract
Single-dose nevirapine (SD NVP) reduces intrapartum HIV-1 transmission, but nonnucleoside reverse transcription (NNRTI) resistance mutations can emerge. Population sequencing among 32 subtype C HIV-1-infected, SD NVP-exposed Zimbawean women demonstrated NNRTI resistance in 25/32 (78%) women: 23/30 (77%) at 2 weeks, 11/31 (35%) at 8 weeks, and 5/27 (19%) at 24 weeks. A total of 447 unique TA clones (median = 28 per time point), from four women with resistance at 8 weeks but wild-type virus by population sequence at 24 weeks, identified NNRTI mutations in a median of 76% (range: 55-96%) of individual clones at 2 weeks, 48% (range: 33-80%) at 8 weeks, and 5% (range: 0-15%) by 24 weeks. NNRTI mutations in breast milk clones at 2 and weeks from one woman varied significantly from plasma. Population sequencing underestimates the diversity of NNRTI resistance mutations within minority populations following SD NVP in subtype C HIV-1 viral RNA in plasma and breast milk.Keywords
This publication has 17 references indexed in Scilit:
- Selection and Persistence of Viral Resistance in HIV-Infected Children After Exposure to Single-Dose NevirapineJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Response to Antiretroviral Therapy after a Single, Peripartum Dose of NevirapineNew England Journal of Medicine, 2007
- Comparison of HIV-1 Mother-to-Child Transmission After Single-Dose Nevirapine Prophylaxis Among African Women With Subtypes A, C, and DJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Breast‐Milk Shedding of Drug‐Resistant HIV‐1 Subtype C in Women Exposed to Single‐Dose NevirapineThe Journal of Infectious Diseases, 2005
- Emergence of Drug‐Resistant HIV‐1 after Intrapartum Administration of Single‐Dose Nevirapine Is Substantially UnderestimatedThe Journal of Infectious Diseases, 2005
- Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral TherapyNew England Journal of Medicine, 2004
- Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)AIDS, 2001
- Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmissionAIDS, 2000
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- Mother-To-Child Transmission Of Human Immunodeficiency Virus Type 1: Report From The Nairobi StudyThe Journal of Infectious Diseases, 1994